Abstract Treatment options for radioiodine resistant metastatic thyroid cancer patients are
limited, and chemotherapy is considered an outdated therapeutic method for differentiated …

Purpose: The purpose of the study was to evaluate the activity and toxicity of cisplatin based
chemotherapy in patients with advanced differentiated thyroid cancer refractory to …

For patients with metastatic differentiated thyroid carcinoma that progresses despite
standard therapies, systemic cytotoxic chemotherapy has traditionally been a limited option …

Background. Outcomes vary among patients with radioiodine refractory (RR) differentiated
thyroid cancer (DTC). The prognostic factors for survival are not well-known, resulting in …

In differentiated thyroid carcinoma refractory to radioactive iodine (CDT-RTI), chemotherapy
has been considered for decades to be the only systemic therapy with palliative purpose …

Treatment of metastatic differentiated thyroid cancer is first based on the use of radioiodine
and thyrotropin-suppressive thyroid hormone treatment. The recent availability of molecular …

Differentiated thyroid carcinomas (DTCs) are generally indolent, but few therapeutic
strategies are available after a metastatic recurrence that is refractory to radioactive iodine …

The cumulative evidence over the past decades has shown that the incidence of
differentiated thyroid carcinoma (DTC) has exponentially increased. Approximately 10% of …

Historically, thyroid cancers have received relatively little attention from the medical
oncology community. As recently as the 2005 Annual Meeting of the American Society of …

The majority of patients with differentiated thyroid cancer are cured with standard primary
treatments including surgery, radioactive iodine and TSH suppression. A small proportion of …